Patent ID: 10266558

Abstract:
Nucleosides and nucleotides (nucleos(t)ides) have been in clinical use for almost 50 years and have become cornerstones of treatment for patients with viral infections or cancer. The approval of several additional drugs over the past decade demonstrates that this family still possesses strong potential. Therefore nucleos(t)ide are of great interest as promising chemotherapeutic agents, including: 2′-deoxy-L-uridine (CAS  31501-19-6), 2′-deoxy-D-uridine (CAS  951-78-0), telbivudine (CAS  3424-98-4), zidovudine (AZT, CAS  30516-87-1), trifluridine (CAS  70-00-8), clevudine (CAS  163252-36-6), PSI-6206 (CAS  863329-66-2), 2′-(S)-2′-chloro-2′-deoxy-2′-fluorouridine (CAS  1673560-41-2), ND06954 (CAS  114248-23-6), stavudine (CAS  3056-17-5), 5-ethynyltavudine (Festinavir, CAS  634907-30-5), torcitabine (CAS  40093-94-5), (−)-beta-D-(2R,4R)-dioxolane-thymine (DOT, 1-((2R,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-5-methyl-2,4(1H,3H)-pyrimidinedione, CAS No. 127658-07-5), 2-(6-amino-purin-9-yl)-ethanol (CAS  707-99-3), 2′-C-methylcytidine (CAS  20724-73-6), PSI-6130 (CAS  817204-33-4), gemcitabine (CAS  95058-81-4), 2′-chloro-2′-deoxy-2′-fluorocytidine (CAS  1786426-19-4), 2′,2′-dichloro-2′-deoxycytidine (CAS  1703785-65-2), 2′-C-methylcytidine (CAS  20724-73-6), PSI-6130 (CAS  817204-33-4), lamivudine (3TC, CAS  134678-17-4), emtricitabine (CAS  143491-57-0), 2′-deoxyadenosine (CAS  958-09-8), 2′-deoxy-β-L-adenosine (CAS  14365-45-8), 2′-deoxy-4′-C-ethynyl-2-fluoroadenosine (CAS  865363-93-5), didanosine (CAS  69655-05-6), entecavir (CAS  209216-23-9), FMCA (CAS  1307273-70-6), dioxolane-G (DOG, CAS  145514-01-8), β-D-2′-deoxy-2′-(R)-fluoro-2′-β-C-methylguanosine (CAS No 817204-45-8), abacavir (ABC, CAS  136470-78-5), dioxolane-A (DOA, CAS #145514-02-9), [(2R,4R)-4-(6-cyclopropylamino-purin-9-yl)-[1,3]dioxolan-2-yl]-methanol (CAS  1446751-04-7), amdoxovir (AMDX, CAS  145514-04-1), (R)-1-(6-amino-purin-9-yl)-propan-2-ol (CAS  14047-28-0), and [(2S,5R)-5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yl]-methanol.Macroheterocyclic nucleoside derivative and its analog of the general formula 1 or general formula 2, a stereoisomer, isotope-enriched analog, pharmaceutically acceptable salt, hydrate, solvate, or crystalline or polymorphic form thereof, wherein:       wherein: R5 is the substituent selected from H, F, Cl, CH3, OH;